10 min listen
Episode 11: Season 2 Highlights
FromA view on
ratings:
Length:
14 minutes
Released:
Oct 31, 2022
Format:
Podcast episode
Description
Join us in celebrating the finale of our second season of A View On, the Lonza podcast.
Over the past few months, we have brought you a series of insider conversations with our experts at Lonza, our partners, and leaders in the industry exploring the new pharma and biotechnology trends. We explored exciting topics, such as oncolytic viruses, the human microbiome, antibody-drug conjugates, nuances of early drug development, capsule manufacturing, and the use of artificial intelligence in the pharma industry.
In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later this year for what is coming up in the next season.
Interested to learn more? Visit our dedicated podcast site on www.lonza.com/a-view-on and don't forget to subscribe.
Over the past few months, we have brought you a series of insider conversations with our experts at Lonza, our partners, and leaders in the industry exploring the new pharma and biotechnology trends. We explored exciting topics, such as oncolytic viruses, the human microbiome, antibody-drug conjugates, nuances of early drug development, capsule manufacturing, and the use of artificial intelligence in the pharma industry.
In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later this year for what is coming up in the next season.
Interested to learn more? Visit our dedicated podcast site on www.lonza.com/a-view-on and don't forget to subscribe.
Released:
Oct 31, 2022
Format:
Podcast episode
Titles in the series (32)
Episode 3: Mesenchymal stem cells for COVID-19 treatment: Mesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute ... by A view on